When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development

Author(s): Zhao-Hui Wu, Yuling Shi

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 18 , 2013

Become EABM
Become Reviewer
Call for Editor


During the last two decades, the studies on ubiquitination in regulating transcription factor NF-κB activation have elucidated the expanding role of ubiquitination in modulating cellular events by non-proteolytic mechanisms, as well as by proteasomal degradation. The significance of ubiquitination has also been recognized in regulating gene transcription, epigenetic modifications, kinase activation, DNA repair and subcellular translocation. This progress has been translated into novel strategies for developing anti-cancer therapeutics, exemplified by the success of the first FDA-approved proteasome inhibitor drug Bortezomib. Here we discuss the current understanding of the ubiquitin-proteasome system and how it is involved in regulating NF-κB signaling pathways in response to a variety of stimuli. We also focus on the recent progress of anti-cancer drug development targeting various steps of ubiquitination process, and the potential of these drugs in cancer treatment as related to their impact on NF-κB activation.

Keywords: Ubiquitin, NF-κB, cancer, therapeutics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 11 April, 2013
Page: [3263 - 3275]
Pages: 13
DOI: 10.2174/1381612811319180010
Price: $65

Article Metrics

PDF: 21